The National Institute for Health and Care Research (NIHR) has awarded £6.5 (£8.7) million, funded jointly through a public-private partnership with the pharmaceutical industry, to establish a UK-wide Commercial Research Delivery Centre (CRDC) Network.  

The new Network will provide strategic coordination of all 21 CRDCs across the four nations of the UK.  

It will play a key role in building research capacity, streamlining the interface between industry and the UK clinical trials delivery infrastructure. 

The CRDCs were announced in December 2024, supported by a public-private funding partnership between government and the pharmaceutical industry.  

The aim of the CRDCs is to accelerate and strengthen commercial clinical research delivery to increase the UK’s global competitiveness in life sciences. Primary Care CRDCs will join the Network in November to support the shift from hospital to community in England. 

Industry funding for the CRDCs is provided via the Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG) Investment Programme, contributing up to £300 ($405) million to boost delivery of commercial clinical trials in the UK. 

The CRDCs work with the life sciences industry and other research infrastructure to deliver commercially sponsored research in the UK. 

Co-ordination of UK clinical trials

According to the NIHR, the Network will: 

  • Provide strategic leadership and national coordination across the 21 CRDCs across the UK. 
  • Offer a central point of contact for industry sponsors. 
  • Facilitate study feasibility, placement and setup across the UK. 
  • Foster collaboration with regulators, wider NIHR and UK-wide delivery infrastructure, and other key stakeholders to advance UK Clinical Research Delivery. 
  • Support workforce development, inclusion, and public involvement. 
  • Facilitate the integration of the Primary Care Commercial Research Delivery Centres (PC-CRDCs) in England in autumn 2025, adopting them into the Network. 

Dr Janet Valentine, Executive Director of Innovation and Research Policy at the Association of the British Pharmaceutical Industry (ABPI), said: “In 2022, industry clinical trials contributed £7.4 ($9.9) billion to the wider UK economy, generating £1.2 ($1.6) billion revenue for the NHS and supporting a total of 65,000 jobs. It is in everyone’s interests that we attract more industry trials to the UK, enabling patients to benefit from participating in trials of the latest innovative treatments.”

Diana Turner, Senior Digital Content Editor, DDW